HHS Launches Psychiatric Overprescribing Action Plan
Key Dates
What Happened
HHS announced a new MAHA action plan on May 4, 2026 aimed at curbing psychiatric overprescribing, with explicit emphasis on children and adolescents. The package includes a Dear Colleague letter encouraging informed consent and shared decision-making, CMS guidance on deprescribing and related reimbursement, and planned SAMHSA, HRSA, NIH, and FDA activities tied to prescribing trends, specialist consultation, and nonmedication treatment access.
Who It Affects
This matters most to pediatric behavioral-health providers, telepsychiatry models, child psychiatrists, and companies whose workflows depend heavily on medication management. It also matters to psychotherapy, family-support, and collaborative-care models that could benefit if CMS and federal agencies put more weight on nonmedication treatment pathways for children and adolescents.
Business Implications
The near-term signal is not a single reimbursement rule. It is a federal posture shift. HHS is framing pediatric psychiatric prescribing as an oversight and practice-pattern issue, which could increase scrutiny on medication-forward behavioral-health models while creating tailwinds for therapy, care-navigation, and specialist-consult models that can show evidence-based alternatives or tighter clinical governance. If CMS follows through on simplifying coverage for psychotherapy and family support services, pediatric mental-health companies with lighter prescribing exposure may be better positioned than medication-centric peers.